280 related articles for article (PubMed ID: 33522825)
1. Ultrasound-Mediated Remotely Controlled Nanovaccine Delivery for Tumor Vaccination and Individualized Cancer Immunotherapy.
Meng Z; Zhang Y; She J; Zhou X; Xu J; Han X; Wang C; Zhu M; Liu Z
Nano Lett; 2021 Feb; 21(3):1228-1237. PubMed ID: 33522825
[TBL] [Abstract][Full Text] [Related]
2. A programmable oral bacterial hydrogel for controllable production and release of nanovaccine for tumor immunotherapy.
Zhang Y; Kang R; Zhang X; Pang G; Li L; Han C; Liu B; Xue X; Liu J; Sun T; Wang T; Liu P; Wang H
Biomaterials; 2023 Aug; 299():122147. PubMed ID: 37182418
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Antitumor Immune Responses via a Self-Assembled Carrier-Free Nanovaccine.
Liu D; Deng B; Liu Z; Ma B; Leng X; Kong D; Ji T; Liu L
Nano Lett; 2021 May; 21(9):3965-3973. PubMed ID: 33886338
[TBL] [Abstract][Full Text] [Related]
4. Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses.
Liu X; Feng Z; Wang C; Su Q; Song H; Zhang C; Huang P; Liang XJ; Dong A; Kong D; Wang W
Biomaterials; 2020 Feb; 230():119649. PubMed ID: 31791843
[TBL] [Abstract][Full Text] [Related]
5. Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer.
Zhou L; Hou B; Wang D; Sun F; Song R; Shao Q; Wang H; Yu H; Li Y
Nano Lett; 2020 Jun; 20(6):4393-4402. PubMed ID: 32459969
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy.
Jiang X; Wang J; Zheng X; Liu Z; Zhang X; Li Y; Wilhelm J; Cao J; Huang G; Zhang J; Sumer B; Lea J; Lu Z; Gao J; Luo M
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35623658
[TBL] [Abstract][Full Text] [Related]
7. Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy.
Zhao P; Xu Y; Ji W; Li L; Qiu L; Zhou S; Qian Z; Zhang H
Int J Nanomedicine; 2022; 17():73-89. PubMed ID: 35027827
[TBL] [Abstract][Full Text] [Related]
8. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
Zhang S; Feng Y; Meng M; Li Z; Li H; Lin L; Xu C; Chen J; Hao K; Tang Z; Tian H; Chen X
Biomaterials; 2022 Oct; 289():121794. PubMed ID: 36113330
[TBL] [Abstract][Full Text] [Related]
9. Nanobiomaterial-based vaccination immunotherapy of cancer.
Chen F; Wang Y; Gao J; Saeed M; Li T; Wang W; Yu H
Biomaterials; 2021 Mar; 270():120709. PubMed ID: 33581608
[TBL] [Abstract][Full Text] [Related]
10. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy.
Zhou S; Huang Y; Chen Y; Liu S; Xu M; Jiang T; Song Q; Jiang G; Gu X; Gao X; Chen J
Biomaterials; 2020 Mar; 235():119795. PubMed ID: 32014739
[TBL] [Abstract][Full Text] [Related]
11. Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination.
Yang R; Xu J; Xu L; Sun X; Chen Q; Zhao Y; Peng R; Liu Z
ACS Nano; 2018 Jun; 12(6):5121-5129. PubMed ID: 29771487
[TBL] [Abstract][Full Text] [Related]
12. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
Yip T; Qi X; Yan H; Chang Y
ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
[TBL] [Abstract][Full Text] [Related]
13. Manganese oxide-constructed multifunctional biomimetic nanovaccine for robust tumor-specific T cell priming and chemodynamic therapy.
Li T; Chen G; Lin L; Li B; Wang X; Chen Y; Huang W; Cai M; Xiao Z; Shuai X; Zhu K
Biomaterials; 2024 Sep; 309():122626. PubMed ID: 38795524
[TBL] [Abstract][Full Text] [Related]
14. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy.
Niu L; Miao Y; Cao Z; Wei T; Zhu J; Li M; Bai B; Chen L; Liu N; Pan F; Zhu J; Wang C; Yang Y; Chen Q
ACS Nano; 2024 Jan; 18(4):3349-3361. PubMed ID: 38230639
[TBL] [Abstract][Full Text] [Related]
15. Acidity-responsive polyphenol-coordinated nanovaccines for improving tumor immunotherapy
Qiu H; Wang S; Huang R; Liu X; Li L; Liu Z; Wang A; Ji S; Liang H; Jiang BP; Shen XC
Biomater Sci; 2024 Jun; 12(12):3175-3192. PubMed ID: 38742916
[TBL] [Abstract][Full Text] [Related]
16. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
[TBL] [Abstract][Full Text] [Related]
17. Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy.
Zhang X; Wang K; Zhao Z; Shan X; Wang Y; Feng Z; Li B; Luo C; Chen X; Sun J
ACS Nano; 2024 Mar; 18(9):7136-7147. PubMed ID: 38407021
[TBL] [Abstract][Full Text] [Related]
18. Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy.
Cai T; Liu H; Zhang S; Hu J; Zhang L
J Nanobiotechnology; 2021 Nov; 19(1):389. PubMed ID: 34823541
[TBL] [Abstract][Full Text] [Related]
19. Dendritic Cell-Based In Situ Nanovaccine for Reprogramming Lipid Metabolism to Boost Tumor Immunotherapy.
Qin YT; Liu XH; An JX; Liang JL; Li CX; Jin XK; Ji P; Zhang XZ
ACS Nano; 2023 Dec; 17(24):24947-24960. PubMed ID: 38055727
[TBL] [Abstract][Full Text] [Related]
20. Self-adjuvanting cancer nanovaccines.
Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
